UPDATE: Section 122 tariff (10%) in effect since Feb 24 — expires ~July 24 (~126 days). 24 states challenge in court (March 5). USTR launches new Section 301 probes (March 11). EU trade deal vote imminent. Full analysis →

🇧🇪

US Tariffs on Pharmaceutical Products from Belgium — 10% (2026)

Tariff Rate Breakdown

10%

Section 122 Base

10%

Total Effective Rate

Pharmaceutical Products from Belgium represent an important segment of bilateral trade, with approximately $50B in total bilateral trade.

Following the Supreme Court's landmark February 20, 2026 decision striking down IEEPA tariffs, imports of pharmaceutical products from Belgium are now subject to a 10% tariff under Section 122 of the Trade Act of 1974, effective February 24, 2026.

This 10% rate has a built-in expiration: Section 122 limits presidential tariff authority to 150 days, meaning the tariff expires approximately July 24, 2026 without congressional renewal.

Pharmaceutical Products (HTS Chapter 30) generally enter duty-free at the MFN level, with the Section 122 tariff as the primary duty. No additional Section 232 or Section 301 surcharges apply to most products in this category from Belgium.

Key products in HTS Chapter 30 imported from Belgium include Vaccines, Antibiotics, Insulin, Bandages, Diagnostic reagents, and Blood products.

Common Products in Chapter 30

VaccinesAntibioticsInsulinBandagesDiagnostic reagentsBlood productsPharmaceutical dosage formsFirst-aid kits

Calculate Your Import Duty

Use our tariff calculator to estimate the exact duty on your pharmaceutical products imports from Belgium.

Open Tariff Calculator

Frequently Asked Questions

What is the current tariff rate on pharmaceutical products from Belgium?

As of March 2026, pharmaceutical products from Belgium face a base tariff of 10% under Section 122. The effective rate can be up to 10%.

Will the tariff on pharmaceutical products from Belgium change?

The Section 122 tariff of 10% expires approximately July 24, 2026, unless Congress extends it. Monitor legislative developments for updates.

How did the Supreme Court ruling affect pharmaceutical products imports from Belgium?

The Supreme Court's February 20, 2026 ruling struck down IEEPA reciprocal tariffs as exceeding presidential authority. The president signed a replacement 10% tariff under Section 122 the same day, effective February 24.